Literature DB >> 17089915

Immunological profiles of patients with chronic myeloid leukaemia. I. State before the start of treatment.

Z Humlová1, H Klamová, I Janatková, P Sandová, I Sterzl, E Sobotková, E Hamsíková, C Haskovec, M Písacka, P Cetkovský, K Michalová, E Faber, Z Hermanová, M Ordeltová, K Roubalová, Z Roth, V Vonka.   

Abstract

In view of the increasing interest in the immunotherapy of CML it seems highly desirable to broaden the present knowledge on the immune reactivity of CML patients. A group of 24 patients and 24 healthy controls were studied for the total of 15 immunological parameters, including the prevalence of antibodies against human herpesviruses and papillomaviruses. To clearly discriminate between changes associated with the disease and those induced by the therapy, all patients were enrolled prior to the start of any anti-leukaemic therapy. Statistically significant differences between patients and controls were found in the levels of IgA, C4 component of complement, CRP and IL-6, the production of Th1 cytokines in stimulated CD3 cells and the E. coli stimulatory index. The analysis of the interrelationship between the results obtained in the individual patients presented some unexpected findings, such as the lack of correlation between the CRP and IL-6 levels. It will be the purpose of a follow-up to determine whether and how the immune status of the patients prior to the treatment correlates with their response to therapy and how the individual immunological profiles change in the course of the disease. These observations will be utilized in the future immunotherapeutic studies to constitute the vaccine- and placebo-treated groups.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17089915

Source DB:  PubMed          Journal:  Folia Biol (Praha)        ISSN: 0015-5500            Impact factor:   0.906


  6 in total

Review 1.  Biological therapy and the immune system in patients with chronic myeloid leukemia.

Authors:  Peter Rohon
Journal:  Int J Hematol       Date:  2012-06-04       Impact factor: 2.490

2.  Kynurenine and uric acid levels in chronic myeloid leukemia patients.

Authors:  Vladimir Vonka; Zuzana Humlova; Hana Klamova; Lenka Kujovska-Krcmova; Martina Petrackova; Eva Hamsikova; Monika Krmencikova-Fliegl; Martina Duskova; Zdenek Roth
Journal:  Oncoimmunology       Date:  2015-03-25       Impact factor: 8.110

3.  Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase.

Authors:  Jirí Pavlů; Andrea K Kew; Beatrice Taylor-Roberts; Holger W Auner; David Marin; Eduardo Olavarria; Edward J Kanfer; Donald H MacDonald; Dragana Milojkovic; Amin Rahemtulla; Katayoun Rezvani; John M Goldman; Jane F Apperley; Richard M Szydlo
Journal:  Blood       Date:  2010-03-19       Impact factor: 22.113

4.  Prognostic importance of single-nucleotide polymorphisms in IL-6, IL-10, TGF-β1, IFN-γ, and TNF-α genes in chronic phase chronic myeloid leukemia.

Authors:  Mustafa Pehlivan; Handan Haydaroglu Sahin; Sacide Pehlivan; Kursat Ozdilli; Leylagul Kaynar; Fatma Savran Oguz; Tugce Sever; Mehmet Yilmaz; Bulent Eser; Yeliz Duvarci Ogret; Cem Kis; Vahap Okan; Mustafa Cetin; Mahmut Carin
Journal:  Genet Test Mol Biomarkers       Date:  2014-05-12

5.  Changes of immunological profiles in patients with chronic myeloid leukemia in the course of treatment.

Authors:  Zuzana Humlová; Hana Klamová; Ivana Janatková; Karin Malíčková; Petra Králíková; Ivan Sterzl; Zdeněk Roth; Eva Hamšíková; Vladimír Vonka
Journal:  Clin Dev Immunol       Date:  2010-12-12

6.  Cytokine Syntheses by T-Cell Subsets From Chronic Myeloid Leukemia Patients: Relationship Between Pre-Treatment Levels and Response to Imatinib Therapy.

Authors:  Inaam B Hassan; Sheela Benedict; Jorgen Kristensen
Journal:  J Hematol       Date:  2018-09-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.